reference/15596542

http://rdf.ncbi.nlm.nih.gov/pubchem/reference/15596542

Outgoing Links

Predicate	Object
contentType	Clinical Trial, Phase III\|Journal Article\|Randomized Controlled Trial\|Research Support, Non-U.S. Gov't
endingPage	394
issn	0923-7534
issueIdentifier	3
pageRange	384-394
publicationName	Annals of oncology : official journal of the European Society for Medical Oncology
startingPage	384
hasFundingAgency	http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_90caa73e5538060f820f129680c611e0 http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_97f5f0db73d6370f569c1a735552c13b
bibliographicCitation	Gogas H, Dréno B, Larkin J, Demidov L, Stroyakovskiy D, Eroglu Z, Francesco Ferrucci P, Pigozzo J, Rutkowski P, Mackiewicz J, Rooney I, Voulgari A, Troutman S, Pitcher B, Guo Y, Yan Y, Castro M, Mulla S, Flaherty K, Arance A. Cobimetinib plus atezolizumab in BRAFV600 wild-type melanoma: primary results from the randomized phase III IMspire170 study. Ann Oncol. 2021 Mar;32(3):384–94. doi: 10.1016/j.annonc.2020.12.004. PMID: 33309774.
creator	http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_8a61427a53c5374edc4b785edd7d1a87 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_5571c66de72c31372dad255006b3bcb5 http://rdf.ncbi.nlm.nih.gov/pubchem/author/ORCID_0000-0002-8920-5429 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_027815475b7f97279d27b54a7a00a5a7 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_dd91d7ba41a28ddae72b1c992cab9867 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_2e0ea4dd22f14960e341695884cb2840 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_55702bd54465ec0c2e9baa741c215359 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_23fc00ca0b0ebc1ed2fb175a81c0230f http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_5ac337eb3a94283e007e2439f948d064 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_b506cd98a45c48356bf428e2a0503ee6 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_e8adc28333ff9936b745803af421e6bd http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_b645c677e7d5e925d1cf73c35cd80755 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_5b0f5b72ffbf795231ba35812b27c263 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_ebb76d998c6a625cd7b1aa3e025563e9 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_874697d68abeef7966159aedceb6ad35 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_4469e7b4f8706b094564eedc75e29c4f http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_5f0ffda87fb89c81e96e381ae3901d03 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_27c255033492d615198fe4b97f749222 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_396b8e4983a257ae32af688058292499 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_2050f61a78bb15b029fb45f8136679f6 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_33c38eac1f55c4e5bd7a5a7b653b7a3e
date	202103
identifier	https://pubmed.ncbi.nlm.nih.gov/33309774 https://doi.org/10.1016/j.annonc.2020.12.004
isPartOf	http://rdf.ncbi.nlm.nih.gov/pubchem/journal/1846 https://portal.issn.org/resource/ISSN/0923-7534
language	English
source	https://www.crossref.org/ https://pubmed.ncbi.nlm.nih.gov/
title	Cobimetinib plus atezolizumab in BRAFV600 wild-type melanoma: primary results from the randomized phase III IMspire170 study
discusses	http://id.nlm.nih.gov/mesh/M0016885 http://id.nlm.nih.gov/mesh/M000600135 http://id.nlm.nih.gov/mesh/M0002072 http://id.nlm.nih.gov/mesh/M000618590 http://id.nlm.nih.gov/mesh/M0029573 http://id.nlm.nih.gov/mesh/M0452142 http://id.nlm.nih.gov/mesh/M0556300
hasPrimarySubjectTerm	http://id.nlm.nih.gov/mesh/D008545Q000235 http://id.nlm.nih.gov/mesh/D048493Q000235 http://id.nlm.nih.gov/mesh/D008545Q000188
hasSubjectTerm	http://id.nlm.nih.gov/mesh/D061067 http://id.nlm.nih.gov/mesh/D006801 http://id.nlm.nih.gov/mesh/D000971Q000009 http://id.nlm.nih.gov/mesh/D010880 http://id.nlm.nih.gov/mesh/D001384
discussesAsDerivedByTextMining	http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8102 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID586 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8607 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6569 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID10030 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID16222096 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7453 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7660 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7429 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID11449 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8448

Total number of triples: 66.